
Jingwu Zang, I-Mab acting CEO
I-Mab expands manufacturing for multiple myeloma antibody; Granules issued 'minor observations' after inspection
China-based biopharma I-Mab has landed a partnership with Shanghai’s Hangzhou Qiantang New Area to manufacture drugs locally and speed up the company’s path toward commercialization.
The deal will help it commercialize felzartamab, a monoclonal antibody that targets multiple myeloma, in China. Hangzhou has started operating on what it calls a Phase I site and started construction in December on an 80,000 square-meter spot for Phase II.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters